Cipla said that it has entered into an exclusive license and supply agreement with Chia Tai Tianqing Pharmaceutical Group Co. for Rolditamig Deuderuxtecan, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).
Cipla inks exclusive licensing agreement with SBP Group for ADC Rolditamig Deuderuxtecan
By Dhallo News · September 1, 2026 at 10:04 AM IST
Original reporting: Business Standard PoliticsRead original report →
Have feedback on this article?Report error or suggestion
